Medicare Plans Should Halt Off-Label Avastin Step Therapy Amid Supply Disruption, CMS Told

 
• By Cathy Kelly
  
Prescribers have long opposed step therapy in the anti-VEGF category. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Medicare

More from Geography